Xiong, Qinmei, Wang, Cen, Liu, Hualong, Tan, Zhaochong, Chen, Chen, Li, Juxiang, Lip, Gregory YH 
ORCID: 0000-0002-7566-1626 and Hong, Kui
(2019)
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asians With Nonvalvular Atrial Fibrillation: A Network Meta-Analysis.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 25.
1076029619885188-.
Abstract
There are few head-to-head trials directly comparing non-vitamin K antagonist oral anticoagulants (NOACs) against one other. A network meta-analysis (NMA) was performed to examine the indirect comparisons among NOACs in Asians with nonvalvular atrial fibrillation (NVAF). STATA 15.0 and ADDIS 1.16.8 softwares were used to perform the statistical analysis. Odds ratios with 95% credible intervals were applied to evaluate the end points. The probabilities of treatment rank were used to understand which interventions are more effective and safe, and the total rank probability was 1. In our NMA, the rank probabilities of apixaban in the case of stroke or systemic embolism, death from any cause, major bleeding, and intracranial hemorrhage (ICH) were 0.47, 0.49, 0.42, and 0.51, respectively. For cases of myocardial infarction, the rank probabilities of rivaroxaban were 0.40. This NMA indirectly compares the main efficacy and safety end points among NOACs in Asians with NVAF, and the rank probability analysis showed that apixaban likely performs best in cases of stroke or systemic embolism, death from any cause, and ICH; rivaroxaban may have the best performance for myocardial infarction.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | atrial fibrillation, Asian, NOACs, indirect comparison, network meta-analysis |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 12 Feb 2020 14:06 |
| Last Modified: | 19 Jan 2023 00:03 |
| DOI: | 10.1177/1076029619885188 |
| Open Access URL: | https://doi.org/10.1177/1076029619885188 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3074694 |
Dimensions
Dimensions
